Jewish ideals and the war

an address delivered by Lucien Wolf on December 7th, 1914

The Jew and Christianity : some phases, ancient and modern, of the Jewish attitude towards Christianity

by Herbert Danby

History of Jewish coinage, and of money in the Old and New Testament

by Frederic W. Madden

A book of jewish thoughts

selected and arr. by the Chief Rabbi (Dr. J.H. Hertz)

Polynesian mythology and ancient traditional history of the New Zealand race as furnished by their priests and chiefs

by Sir George Grey, late governor-in-chief in New Zealand

Bericht an den XIX. Zionistenkongress und an den Council der Jewish Agency for Palestine in Luzern

The Jewish Agency for Palestine, Central Bureau for the Settlement of German Jews. Hrsg. vom Zentralbüro für die Ansiedlung deutscher Juden in Palästina

Parody in Jewish literature

by Israel Davidson

Jewish life in oriental countries : a list of books and manuscripts exhibited at the New York public library March 30th to December 31st, 1926

Prepared and arranged by Joshua Bloch

New Judea : Jewish life in modern Palestine and Egypt

by Benjamin L. Gordon

Jesus of Nazareth in the light of Jewish and Christian thought and history : a sunday lecture delivered January 10, 1926

by Samuel H. Goldenson

Discourses, argumentative and devotional, on the subject of the Jewish religion : delivered at the synagogue Mikveh Israel

by Isaac Leeser

Sayings of the Jewish Fathers : comprising Pirqe Aboth and Pereq R. Meir ; ... with ... specimen pages of the Cambridge University manuscript of the Mishnah 'Jerushalmith' from which the text of Aboth is taken

by Charles Taylor

Jewish literature

from the German of M. Steinschneider

Response to chemotherapy, recurrence and survival in advanced-stage ovarian, fallopian tube and primary peritoneal cancer patients with non-Ashkenazi Jewish BRCA mutations, compared to those without

Objectives. Previous studies have shown a survival advantage in ovarian cancer patients with Ashkenazi-Jewish (AJ) BRCA founder mutations, compared to sporadic ovarian cancer patients. The purpose of this study was to determine if this association exists in ovarian cancer patients with non-Ashkenazi Jewish BRCA mutations. In addition, we sought to account for possible "survival bias" by minimizing any lead time that may exist between diagnosis and genetic testing. ^ Methods. Patients with stage III/IV ovarian, fallopian tube, or primary peritoneal cancer and a non-Ashkenazi Jewish BRCA1 or 2 mutation, seen for genetic testing January 1996-July 2007, were identified from genetics and institutional databases. Medical records were reviewed for clinical factors, including response to initial chemotherapy. Patients with sporadic (non-hereditary) ovarian, fallopian tube, or primary peritoneal cancer, without family history of breast or ovarian cancer, were compared to similar cases, matched by age, stage, year of diagnosis, and vital status at time interval to BRCA testing. When possible, 2 sporadic patients were matched to each BRCA patient. An additional group of unmatched, sporadic ovarian, fallopian tube and primary peritoneal cancer patients was included for a separate analysis. Progression-free (PFS) & overall survival (OS) were calculated by the Kaplan-Meier method. Multivariate Cox proportional hazards models were calculated for variables of interest. Matched pairs were treated as clusters. Stratified log rank test was used to calculate survival data for matched pairs using paired event times. Fisher's exact test, chi-square, and univariate logistic regression were also used for analysis. ^ Results. Forty five advanced-stage ovarian, fallopian tube and primary peritoneal cancer patients with non-Ashkenazi Jewish (non-AJ) BRCA mutations, 86 sporadic-matched and 414 sporadic-unmatched patients were analyzed. Compared to the sporadic-matched and sporadic-unmatched ovarian cancer patients, non-AJ BRCA mutation carriers had longer PFS (17.9 & 13.8 mos. vs. 32.0 mos., HR 1.76 [95% CI 1.13–2.75] & 2.61 [95% CI 1.70–4.00]). In relation to the sporadic- unmatched patients, non-AJ BRCA patients had greater odds of complete response to initial chemotherapy (OR 2.25 [95% CI 1.17–5.41]) and improved OS (37.6 mos. vs. 101.4 mos., HR 2.64 [95% CI 1.49–4.67]). ^ Conclusions. This study demonstrates a significant survival advantage in advanced-stage ovarian cancer patients with non-AJ BRCA mutations, confirming the previous studies in the Jewish population. Our efforts to account for "survival bias," by matching, will continue with collaborative studies. ^